Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-014366
Filing Date
2023-05-15
Accepted
2023-05-15 09:15:37
Documents
65
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atos20230331_10q.htm   iXBRL 10-Q 857722
2 EXHIBIT 31.1 ex_473330.htm EX-31.1 11188
3 EXHIBIT 31.2 ex_473331.htm EX-31.2 11080
4 EXHIBIT 32.1 ex_473332.htm EX-32.1 5891
5 EXHIBIT 32.2 ex_473333.htm EX-32.2 5991
11 p01.jpg GRAPHIC 233260
  Complete submission text file 0001437749-23-014366.txt   4730251

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA atos-20230331.xsd EX-101.SCH 45788
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE atos-20230331_cal.xml EX-101.CAL 27573
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230331_def.xml EX-101.DEF 284085
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230331_lab.xml EX-101.LAB 250228
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230331_pre.xml EX-101.PRE 309423
59 EXTRACTED XBRL INSTANCE DOCUMENT atos20230331_10q_htm.xml XML 458390
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 23918941
SIC: 2834 Pharmaceutical Preparations